Synthesis of Commercial Phosphodiesterase(V) Inhibitors

@article{Dunn2005SynthesisOC,
  title={Synthesis of Commercial Phosphodiesterase(V) Inhibitors},
  author={P. Dunn},
  journal={Organic Process Research & Development},
  year={2005},
  volume={9},
  pages={88-97}
}
  • P. Dunn
  • Published 2005
  • Chemistry
  • Organic Process Research & Development
The literature syntheses (including patents) of three commercial phosphodiesterase(V) (PDE5) inhibitors (sildenafil, vardenafil, and tadalafil) are reviewed with particular emphasis on large-scale manufacture. For each of these compounds, some impressive chemical development work has been reported. 
View via Publisher
organica1.org
47 Citations
Background Citations
3

Figures and Tables from this paper

Paper Mentions

Blog Post
Sildenafil citrate: Entity of the Month
O'Really?
4 March 2010

47 Citations

Citation Type

Citation Type

Development on the Synthesis of Phosphodieseterase Type 5 (PDE5) Inhibitors
The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
Synthesis of isotope – labeled selective PDE5 inhibitor sildenafil (UK 92480-10)
An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles
Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Alternative method for the synthesis of imidazo[5,1-f][1,2,4]triazin-4(3H)-one—a substrate for the preparation of phosphodiesterase (5) inhibitors
Synthesis of tadalafil (Cialis) from L-tryptophan
Identification, synthesis, and characterization of potential genotoxic impurities of sildenafil citrate drug substance
An Efficient and General Method for the Stereodivergent Syntheses of Tadalafil-Like Tetracyclic Compounds
Chapter 8 - Tadalafil
...
1
2
3
4
5
...

References

SHOWING 1-2 OF 2 REFERENCES
Chinese Patent CN 99 - 111153 ,
  • 2001
World Patent , WO 04 / 011463 . Scheme 14 . Building blocks for tadalafil Scheme 15